

MedReleaf completes first international export

Pioneering transaction also marks first ever cannabis oil import to Brazil

Markham, Ontario, August 8, 2017 – MedReleaf Corp. (TSX: LEAF) (MedReleaf or the “Company”), North America’s first and only ISO 9001 and ICH-GMP certified producer of cannabis-based pharmaceutical products, today announced a milestone achievement with the completion of its first international export. The transaction is also noteworthy as the first ever import of medical cannabis oil to Brazil and serves as a demonstration of both the Company’s commitment to international growth and to establishing its position as the leading source of cannabis-based pharmaceutical products globally.

The export is being made to treat the symptoms of Sofia Langenbach, a child who carries the CDKL5 genetic syndrome – leading her to experience refractory epilepsy and severe seizures which for her, has only been alleviated by the use of medical cannabis. Her mother, Ms. Margarete Santos de Brito, currently president of APEPI (“Support for Research and Medical Cannabis Patients”), the first and largest Association of Cannabis patients in Brazil, previously won a landmark Brazilian court case to cultivate her own cannabis and has been one of the leading activists advocating for the legalization of medical cannabis in Brazil for many years.

“We have been working with Margarete Santos De Brito (president of Brazilian NGO APEPI), who has been a tireless, high-profile public champion of medical cannabis and whose daughter Sofia is in dire need of cannabis-based pharmaceutical products to manage her symptoms.” said Neil Closner, CEO of MedReleaf. “We are proud that Ms. Santos and ANVISA, the Brazilian Government’s National Health Surveillance Agency, have put their faith in MedReleaf.”

“This is an important step in achieving MedReleaf’s goals of ensuring that patients in need around the world receive the highest quality cannabis-based pharmaceutical products available and in realizing our long-term growth plans.” continued Closner.

“I am very thankful we received this first import of MedReleaf’s medical grade cannabis oil for Sofia” said Ms. Santos.

##

About MedReleaf

MedReleaf sets *The Medical Grade Standard™* for cannabis in Canada and around the world. The first and only ICH-GMP and ISO 9001 certified producer of cannabis-based pharmaceutical products in North America, MedReleaf is a R&D-driven company dedicated to patient care, scientific innovation, research and advancing the understanding of the therapeutic benefits of cannabis. Sourced from around the world and perfected in one of two state of the art facilities in Ontario, MedReleaf delivers a variety of premium products to patients seeking safe, consistent and effective medical cannabis.

For more information on MedReleaf, its products, research and how the company is helping patients #livefree, please visit MedReleaf.com or follow @medreleafcanada.

Forward Looking Statements

This press release contains "forward-looking information" within the meaning of applicable Canadian securities legislation which are based upon MedReleaf's current internal expectations, estimates, projections, assumptions and beliefs and views of future events. Forward-looking information can be identified by the use of forward-looking terminology such as "expect", "likely", "may", "will", "should", "intend", "anticipate", "potential", "proposed", "estimate" and other similar words, including negative and grammatical variations thereof, or statements that certain events or conditions "may", "would" or "will" happen, or by discussions of strategy. Forward-looking information include estimates, plans, expectations, opinions, forecasts, projections, targets, guidance or other statements that are not statements of fact.

Any forward-looking information speaks only as of the date on which it is made, and, except as required by law, MedReleaf does not undertake any obligation to update or revise any forward-looking information, whether as a result of new information, future events or otherwise. New factors emerge from time to time, and it is not possible for MedReleaf to predict all such factors. When considering these forward-looking statements, readers should keep in mind the risk factors and other cautionary statements in MedReleaf's Final Long Form Prospectus dated May 30, 2017 and filed with the applicable Canadian securities regulatory authorities on SEDAR at www.sedar.com. The risk factors and other factors noted in MedReleaf's Final Long Form Prospectus could cause actual events or results to differ materially from those described in any forward-looking information.

Contact information:

Dennis Fong, Investor Relations, investorrelations@medreleaf.com, 416-283-9930